Latest News & Features
Biotechnology
James Love was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports. 5 October 2016
Asia
Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports. 5 October 2016
Europe
A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker. 20 September 2016
Big Pharma
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC. 16 September 2016
Big Pharma
The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins. 13 September 2016
Asia
An increasing number of biologics and biosimilar products are appearing in the Thai market, but there are challenges concerning IP protection and regulation, say Alan Adcock and Atthachai Homhuan of Tilleke & Gibbins. 8 September 2016
Europe
Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter. 6 September 2016
Big Pharma
While we await the outcome of the appeal in Warner-Lambert v Actavis, which concerns second medical use patents, there are several steps drugs companies should take given the need to balance the interests of patent owners and generic makers. Clare Greatbanks of Osborne Clarke reports. 1 September 2016
Big Pharma
The consequences of the Brexit vote for the life sciences sector will depend on the UK’s relationship with the EU once the negotiations are concluded, as Christina Guazzi and Nina Schäffner of Freshfields Bruckhaus Deringer explain. 25 August 2016
Americas
Although recent Federal Circuit decisions on the ‘patent dance’ provide some clarity, the BPCIA still presents difficult and hotly debated issues of interpretation. Stacie Ropka, William Rose and Ryan Hersh of Axinn, Veltrop & Harkrider report. 23 August 2016